132945-78-9

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-BOC-3-Cyanopyrrolidine is used as a reagent for the production of pharmaceuticals and other fine chemicals. Its cyanopyrrolidine group provides a reactive site for further chemical modification, making it a versatile intermediate in organic chemistry.
Used in Organic Synthesis:
(S)-1-BOC-3-Cyanopyrrolidine is used as a building block in the synthesis of various organic compounds. The BOC protecting group allows for selective reactions to occur at the cyano group, facilitating the creation of more complex molecules in organic chemistry.

InChI:InChI=1/C10H16N2O2/c1-10(2,3)14-9(13)12-5-4-8(6-11)7-12/h8H,4-5,7H2,1-3H3/t8-/m1/s1

Upstream product

• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 773837-37-9 sodium cyanide 
• 127423-61-4 tert-butyl (3R)-3-methylsulfonyloxypyrrolidine-1-carboxylate 
• 109431-87-0 (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate 

Downstream Products

• 199174-29-3 tert-butyl (R)-3-(aminomethyl)pyrrolidine-1-carboxylate 
• 1352661-27-8 C₁₉H₂₅N₅O₇ 
• 140148-70-5 (S)-1-N-boc-β-proline 

Relevant academic research and scientific papers

Novel pyrrolidine or piperidine derivatives having activity for T-type calcium channel

A pyrrolidine or piperidine compound having activity for T - type calcium channel, wherein the pyrrolidine or piperidine compound of Formula 1 according to the present invention has an excellent antagonistic activity to, T-type calcium channel, and can be used as a preventive or therapeutic agent, for pain diseases, or cancer related to cancer, or cancer such as, epilepsy and,hepatic pain, angina. (by machine translation)

Asymmetric Hydrocyanation of Alkenes without HCN

A general and efficient rhodium-catalyzed asymmetric cyanide-free hydrocyanation of alkenes has been developed. Based on the asymmetric hydroformylation/condensation/aza-Cope elimination sequences, a broad scope of substrates including mono-substituted, 1,2-, and 1,1-disubstituted alkenes (involving natural product R- and S-limonene) were employed, and a series of valuable chiral nitriles are prepared with high yields (up to 95 %) and enantioselectivities (up to 98 % ee). Notably, the critical factor to achieve high enantioseletivies is the addition of catalytic amount of benzoic acid. This novel methodology provides an efficient and concise synthetic route to the intermediate of vildagliptin and anagliptin.

Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain

The treatment of neuropathic pain is one of the urgent unmet medical needs and T-type calcium channels are promising therapeutic targets for neuropathic pain. Several potent T-type channel inhibitors showed promising in vivo efficacy in neuropathic pain a

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.

CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY

The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) wherein each of R1, R3, R20, X1, X2, Z, W, (a) and (q) have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of turnours which are sensitive to inhibition of erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds

1-Azabicyclo[3.2.0]hept-2-ene-2-carboxyic acids having antimicrobial activity have been prepared.